Clinical Trial Update: In Vivo Persistence of Adoptively-Transferred TIL Cultured With Akti in People With Metastatic Melanoma [Phase 1]

View source ↗

Summary

The Phase 1 trial of adoptively transferred tumor-infiltrating lymphocytes cultured with an Akt inhibitor for metastatic melanoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Akti (Akt inhibitor)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Metastatic Melanoma | Phase 1 | Status: WITHDRAWN